Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study

Affiliations

¹ Georgia Cancer Center, Augusta, GA. jorge.cortes@augusta.edu.
² Princess Margaret Cancer Centre, Toronto, ON.
³ Georgia Cancer Center, Augusta, GA.
⁴ Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna.
⁵ McGill University, Montreal, QC.
⁶ Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University Hospital, Aachen, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD).
⁷ Pfizer Inc, Cambridge, MA.
⁸ Pfizer SLU, Madrid.
⁹ University of Milano-Bicocca, Monza.

Clinical Trial

Jorge E Cortes et al. Haematologica. 2023.

. 2023 Dec 1;108(12):3454-3459.

doi: 10.3324/haematol.2022.281944.

¹ Georgia Cancer Center, Augusta, GA. jorge.cortes@augusta.edu.
² Princess Margaret Cancer Centre, Toronto, ON.
³ Georgia Cancer Center, Augusta, GA.
⁴ Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna.
⁵ McGill University, Montreal, QC.
⁶ Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University Hospital, Aachen, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD).
⁷ Pfizer Inc, Cambridge, MA.
⁸ Pfizer SLU, Madrid.
⁹ University of Milano-Bicocca, Monza.

No abstract available

References

1. Garcia-Gutierrez V, Hernandez-Boluda JC. Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol. 2019;9:603. - PMC - PubMed
1. Cortes JE, Kantarjian HM, Brummendorf TH, et al. . Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118(17):4567-4576. - PMC - PubMed
1. Khoury HJ, Cortes JE, Kantarjian HM, et al. . Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012;119(15):3403-3412. - PMC - PubMed
1. Gambacorti-Passerini C, Kantarjian HM, Kim DW, et al. . Longterm efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015;90(9):755-768. - PMC - PubMed
1. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. . Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231-237. - PMC - PubMed